Anika Therapeutics is a medical instruments & supplies business based in the US. Anika Therapeutics shares (ANIK) are listed on the NASDAQ and all prices are listed in US Dollars. Anika Therapeutics employs 357 staff and has a trailing 12-month revenue of around $166.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $24.56 |
|---|---|
| 52-week range | $16.54 - $29.12 |
| 50-day moving average | $26.33 |
| 200-day moving average | $24.88 |
| Wall St. target price | $32.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-5.06 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $24.56 from 2024-09-06
| 1 week (2024-08-30) | -4.44% |
|---|---|
| 1 month (2024-08-07) | -5.36% |
| 3 months (2024-06-07) | -4.77% |
| 6 months (2024-03-07) | -3.12% |
| 1 year (2023-09-07) | 42.29% |
|---|---|
| 2 years (2022-09-07) | 5.86% |
| 3 years (2021-09-07) | 40.07 |
| 5 years (2019-09-06) | 55.2 |
Valuing Anika Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Anika Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Anika Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.573. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Anika Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Anika Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.3 million.
The EBITDA is a measure of a Anika Therapeutics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $166.9 million |
|---|---|
| Operating margin TTM | 0.38% |
| Gross profit TTM | $96.8 million |
| Return on assets TTM | 0.01% |
| Return on equity TTM | -30.63% |
| Profit margin | -44.45% |
| Book value | $14.18 |
| Market Capitalization | $380.3 million |
TTM: trailing 12 months
We're not expecting Anika Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Anika Therapeutics's shares have ranged in value from as little as $16.54 up to $29.115. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anika Therapeutics's is 0.827. This would suggest that Anika Therapeutics's shares are less volatile than average (for this exchange).
Anika Therapeutics, Inc. , a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.